CG Oncology Gains 12% in Three Months as BLA Filing Nears, but Manufacturing and Regulatory Risks Loom

What happened

CG Oncology stock has risen about 12% over the past three months, driven by optimism around its lead candidate cretostimogene for bladder cancer. The company is nearing completion of a rolling BLA submission for high-risk BCG-unresponsive NMIBC and has reported encouraging Phase II data. However, the DeepValue report highlights a critical gating risk: the company has changed third-party manufacturers and is 'unable to demonstrate full comparability between lots,' which may delay or block BLA submission. Additionally, the pivotal Phase III PIVOT-006 trial topline data is expected in the first half of 2026, and any slip past June 30 would undermine the near-term catalyst narrative. Despite a strong cash position ($742M), the stock's current valuation of ~$57 embeds substantial success assumptions that do not account for these unresolved CMC and regulatory hurdles.

Implication

The near-term catalyst-driven rally may extend into the PIVOT-006 readout, but the risk-reward is unattractive today. The DeepValue report's identified CMC comparability issue means the BLA may not be complete in 2026, and the FDA could require additional trials. Investors should not chase the recent momentum; instead, wait for either (1) the PIVOT-006 topline data in 1H 2026 with clean results, or (2) explicit disclosure that the rolling BLA has advanced to module submissions or that CMC lot comparability has been resolved. Until then, the stock's premium pricing lacks a sufficient margin of safety, and a slip in timeline could trigger a 20-30% drawdown.

Thesis delta

The DeepValue report's WAIT thesis remains intact; the Zacks article merely validates the market's existing positive sentiment without addressing the CMC comparability risk. The thesis delta is that the recent price action further embeds the optimistic 'catalyst soon' narrative, making the stock more vulnerable to disappointment if PIVOT-006 misses the June 30 deadline or if CMC issues emerge. The risk of a negative surprise has increased as the stock has risen on hopes rather than fundamental de-risking.